Additional file 4: Table S2. of Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial LacostaAna-María Pascual-LucasMaría PesiniPedro CasabonaDiego Pérez-GrijalbaVirginia Marcos-CamposIván SarasaLeticia CanudasJesus BadiHassnae MonleónInmaculada San-JoséItziar MunueraJosep Rodríguez-GómezOctavio AbdelnourCarla LafuenteAsunción BuendíaMar BoadaMercè TárragaLluis RuizAgustín SarasaManuel 2018 Relationship of adverse events (AEs) with the treatment. (DOCX 15 kb)